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The aim of this study was to evaluate a wide panel of antigens of Mycobacterium avium subsp. paratuberculosis (MAP) to select
candidates for the diagnosis of paratuberculosis (PTB). A total of 54 recombinant proteins were spotted onto nitrocellulose
membranes and exposed to sera from animals with PTB (n = 25), healthy animals (n = 10), and animals experimentally infected
with M. bovis (n = 8). This initial screening allowed us to select seven antigens: MAP 2513, MAP 1693, MAP 2020, MAP 0038,
MAP 1272, MAP 0209c, and MAP 0210c, which reacted with sera from animals with PTB and showed little cross-reactivity with
sera from healthy animals and animals experimentally infected with M. bovis. The second step was to evaluate the antigen cocktail
of these seven antigens by ELISA. For this evaluation, we used sera from animals with PTB (n = 25), healthy animals (n = 26),
and animals experimentally infected with M. bovis (n = 17). Using ELISA, the cocktail of the seven selected MAP antigens reacted
with sera from 18 of the 25 animals with PTB and did not exhibit cross-reactivity with healthy animals and only low reactivity
with animals with bovine tuberculosis. The combined application of these antigens could form part of a test which may help in
the diagnosis of PTB.
1. Introduction
PTB is a prevalent and economically important disease that
affects cattle and thus impacts on the cattle industry. It is
caused by MAP.
Clinical PTB is characterized by chronic granulomatous
enteritis with clinical signs of diarrhea, weight loss, decreased
milk production, and mortality. However, most infected
cattle show no clinical signs during the prolonged incubation
stage of infection [1].
On the other hand, a number of theories have proposed
that the principal infective agent of Crohn’s disease, a chronic
enteropathy in humans, is MAP [2–4]. The economic impact
and possible link to Crohn’s disease highlights the impor-
tance of the development of control programs at the herd
level. To this end, it is necessary to improve the diagnostic
methods of PTB.
Cattle are most often infected as young calves, before 6
month of age, but some studies have shown that infection
may also occur in adult cattle. Fecal shedding of MAP
generally starts after 2 years, and clinical symptoms appear
after an incubation period of 2–10 years. In addition, the
elimination of the agent through the stool is very variable
[5].
Cell-mediated immune response wanes with progression
of the disease and when this occurs, a humoral immune
response becomes measurable. It has been shown that cattle
are more likely to have a combined antibody and cellular
response rather than a switch from cellular to antibody
response [6–8]. Among tests to detect serum antibody to
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MAP, ELISAs are the most widely used. Several commercial
ELISA kits for bovine PTB are currently available, and
multiple studies have compared their accuracy [9, 10].
Comparative studies of ELISAs with different antigens have
shown discrepancies in the ability of these tests to identify all
infected animals [11]. Some authors have suggested that this
may be due to the lack of representation of the entire range
of immunodominant antigens for MAP in a given ELISA
test [12]. Then, one of the crucial components of this test
is the antigen used for the preparation of the ELISA test.
The antigen most widely used for the serological diagnosis of
PTB is PPA-3, which is the M. avium strain 18 protoplasmic
antigen. Currently, antigen-based tests to detect MAP with
a mixture of proteins include whole-cell sonicated extract,
parcel purified antigen, and protoplasmic antigens. These
antigens show variability in potency and cross-reaction.
This diagnostic method has drawbacks due to the cross-
reaction with animals sensitized with this mycobacterium
or other pathogens antigenically related to MAP [11]. Since
the sequencing and analysis of the entire MAP genome was
obtained [13], several specific proteins have been detected
in the genome of MAP and the immunoreactivity of these
proteins investigated [14]. Bannantine et al. [15] developed
a spot protein array for initial antigen screening. Available
diagnostic MAP antigens are reviewed in Mikkelsen et al.
[16]. However, individual antigens are able to identify only
a subset of PTB-infected animals. Then, a mix of antigens
could be a good candidate for serological diagnosis.
In the present work, MAP antigens were obtained after
fractionating proteins from the whole cell or membrane
or secreted fraction, resolved with two-dimensional gels,
printed in line onto nitrocellulose membranes, and analyzed
with sera from animals with PTB.
MAP proteins recognized specifically by sera from PTB-
infected animals were used to develop a cocktail of selected
antigens to be evaluated by ELISA.
2. Material andMethods
2.1. Animals. Sera from a total of 43 animals from different
groups (a) cattle coming from PTB-free herds and with
MAP negative fecal cultures (negative control animals) (n =
10), (b) cattle naturally infected, with MAP-positive fecal
cultures or ELISA-positive tests (n = 25), and (c) animals
experimentally infected with M. bovis with lesions (n = 8)
were used to evaluate the 54 recombinant proteins of MAP.
The final screening using a cocktail of seven selected
antigens was carried out with sera from 68 cattle: 25 cows
with MAP positive fecal culture or ELISA-positive tests, 26
cows from negative herds with no suspected cases of PTB
and negative tests (fecal cultures, serology and INF-g), and
17 from animals experimentally infected with M. bovis and
with lesion at the time of necropsy.
2.2. Selection of Antigens. With the aim of identifing and
characterizing immunoreactive proteins for their possible
use in diagnosis, we extracted proteins of MAP by treatment
of cells with sodium dodecyl sulfate at 50◦C [17]. The
proteins were resolved by one- or two-dimensional SDS-
PAGE, carried out in duplicate. Both duplicates were stained
with colloidal Coomassie blue and the other was transferred
to a nitrocellulose membrane (Amersham Hybond-ECL, GE
Healthcare Life Sciences, Buckinghamshire, UK) to perform
a Western blot with a PTB-positive bovine serum sample.
Six proteins were immunoreactive with sera from animals
with PTB and as nonimmunoreactive with sera from animals
infected withM. avium. These proteins were cut from the gel
and identified by MALDI TOF. This study identified these
proteins as encoded by MAP 1962 (Glutamine synthetase),
MAP 4143 (Elongation factor tu), MAP 0187c (SodA), MAP
3194, MAP 3205, and MAP 3206, as potential diagnostic
antigens.
The other 48 proteins here evaluated were from CIDC-
Lelystad, Central Institute for Animal Disease Control
Department Bacteriology, and TSEs, Lelystad, the Nether-
lands.
2.3. Recombinant Antigens. The 54 proteins were produced
as recombinant. Briefly, they were cloned and purified
essentially as described previously [18], where all proteins
were PCR-cloned using 5′- and 3′-primers amplifying DNA
fragments encoding the mature protein except for secreted
proteins, which were cloned without the signal peptide. The
DNA fragments were cloned into expression vectors. The
antigens were cloned into the pET33b (Novagen Inc., Madi-
son, WI, USA) and pRSET (Invitrogen Corp., Carlsbad, CA,
USA) vectors, and expression was induced by the production
of T7 RNA polymerase in BL21 (DE3) E. coli. These cells
also produce T7 lysozyme to reduce the basal expression
of the target genes. The secreted antigens described in
Willemsem et al. [18] (MAP 2609, MAP 2942c and MAP
0210c) were cloned in pQE80 (Qiagen, Germantown, MD,
USA). Antigens were purified using their histidine-tagged N-
terminal region and Nickel-affinity columns, (1mL HisTrap
HP columns) (GEHealthcare Life Sciences, UK). Before that,
solubilization of the recombinant antigen was established by
a buffer containing 6M Guanidine, 20mM Tris (pH 8.0),
0.5M NaCl, or 50mM Imidazol, 0.25% CHAPS, 1mMDTT,
0.5mM PMSF, and 1% iso-propanol to solve proteins from
inclusion bodies (Guanidine), reduce nonspecific binding
(Imidazol), and decrease the amount of LPS (iso-propanol)
or 8M Urea. After affinity-purification, the antigens were
dialyzed (10 kDa cut-off, except for Map 4000c, for which
a 1 kDa cut-off was used) against a buffer containing 0 to
6M Urea, 10mM Tris (pH 8.0), 25% glycerol, 1mM DTT,
0.5mM PMSF, 1% iso-propanol or 0 to 7M Urea, 10mM
Tris (pH 8.0), 10% glycerol, 1mM DTT, 0.5mM PMSF, and
1% iso-propanol. The urea concentration was the minimal
concentration needed to keep the proteins solubilized and
determined empirically.
The recombinant proteins were analyzed by Coomassie-
stained SDS-PAGE to test purity.
2.4. Coomassie Blue Staining. A gel containing six of the
recombinant purified proteins included in the cocktail is
shown in Figure 1. The protein encoded by MAP 0209c
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Figure 1: Recombinant proteins analyzed by coomassie-stained
SDS-PAGE to test purity.
(of 56.5 kDa) is shown on the first lane but is not visible
because it is very close to the front of the run. The proteins
were run in a 15% polyacrylamide gel and then incubated
in a Coomassie blue solution 0.05% (Coomassie brilliant
blue R250 0.05%, methanol 50%, acid acetic 10%) for 1.5
hours with agitation. The Coomassie blue solution was then
removed and bleached with bleaching solution (methanol
50%, acetic acid 10%).
2.5. Evaluation of Humoral Response by a Line Print Im-
munoassay. The panel of 54 proteins was evaluated as
follows: 20 µL of each antigen was applied to a nitrocellulose
membrane at a concentration of 100 µg/mL, using a semi-
automatic aerosolizer (Camag Scientific Inc., Wilmington,
Delaware). The membranes were blocked with 50mL of
blocking solution (5% milk TBS) for 1 h. The membranes
were then placed in a “miniblotter” (Isogen BioSolutions,
the Netherlands). This allowed parallel analysis of 45 sera.
We evaluated serum dilutions of 1 : 100. After 1 h incubation,
the serum samples were aspirated and washed three times
for 10min with TBS 1x. The membrane was then incubated
for 1 h with protein G conjugated to peroxidase (1 : 1500).
The membrane was washed three times for 10 min with TBS
1X and revealed by chemiluminescence (Pierce ECL western
blotting, Thermo Scientific, USA).
Line print immunoassay generated macroarrays of re-
combinant proteins which were evaluated with sera from ani-
mals with PTB. In order to identify potentially cross-reactive
proteins, the macroarrays were also used to probe against
sera from healthy animals and from animals experimentally
infected with M. bovis. The macroarrays were subjected to
densitometry analysis to provide quantification for reactivity
at each spot, reported as spot intensities.
2.6. Bioinformatic and Statistical Ana´lisis. The panel of
54 recombinant proteins included in the present study
was characterized in silico: molecular weight, location
prediction, and homology with other mycobacterial pro-
teins (Table 1). PSORTb analysis was used to predict pro-
tein localization based on a number of factors includ-
ing transmembrane helices, signal peptide, motif search,
and similarity to proteins with known subcellular loca-
tion. (http://www.psort.org/psortb/). According to PSORTb
prediction, the set of recombinant proteins contains 28
cytoplasmic proteins, 7 cytoplasmic andmembrane proteins,
6 extracellular proteins, and 13 proteins with uncertain
localization (Table 1).
BLAST similarity searches were performed locally on
coding sequences by comparison with the GenBank nonre-
dundant protein database (Table 1).
2.7. Measurement of Spot Intensities. Quantitative spot inten-
sities were obtained by performing a densitometric scan of
the membrane. For the analysis of the results, the intensities
of the points were measured with the ImageQuant TL Array
Version 7.0 Software, (GE Healthcare, Pittsburgh, PA).
This quantification software processes spot intensities on
the array and determines themean intensities of pixels within
a spot as well as those of the background pixels around the
spot. These local-background intensities are subtracted from
the raw signals to obtain the local-background-corrected
levels. The measured diameter that was selected for scans of
different arrays was consistent for all the arrays in this study.
Adjusted intensities were obtained following normalization
of each spot. Five proteins (MAP 0038, MAP 1272, MAP
1693, MAP 0210c, and MAP 0209c) showed a stronger mean
intensity with sera from MAP-infected animals than with
sera from non-MAP-infected animals and were thus selected
for a cocktail of antigens (Table 2).
MAP 2020 and MAP 2513 were also selected because
although they did not show a strong intensity with sera
from MAP-infected animals, they recognized nine and six
animals with PTB, respectively (Table 3), and because these
proteins had not been previously evaluated or reported in the
literature.
2.8. ELISA. The antigens used for the ELISA test were PPA-
3 (Allied Monitor, Inc. USA) and a cocktail with the seven
antigens selected (MAP 2513, MAP 1693, MAP 2020, MAP
0038, MAP 1272, MAP 0209c, andMAP 0210c). The cocktail
was prepared with 30 µg of each antigen for 1mL of the
mixture. The microtiter plates were coated at 4◦C overnight
with 100 µL of 40 µg/mL PPA-3 or 20 µg/mL of the cocktail in
carbonate buffer (pH: 9.6). Then, the plates were saturated
with 100 µL of PBS/0.5% w/v gelatin for 1 h at 37◦C, then
washed five times with PBS/0.1% Tween20 (PBS/T), and
incubated for 1 h at 37◦C with 100 µL of 100-fold dilution of
sera in PBS/T containing 0.5% (w/v) gelatin. The plates were
then washed five times with PBS/T and incubated for 30min
at 37◦C with 100 µL of 1500-fold dilution of peroxidase-
conjugated protein in PBS/T containing 0.5% (w/v) gelatin.
Plates were washed five times with PBS/T, and 50 µL of
peroxidase substrate was added. Optical density (OD) was
measured at 405 nm.
3. Results
54 proteins were evaluated by Line print immunoassay with
sera from healthy animals, animals with PTB, and animals
4 Veterinary Medicine International
Table 1: Characterization in silico of a panel of 54 recombinant proteins, included in the present study.
Antigen
(ORF no.)
Predicted localization
Theoretical
MW
Homology with other mycobacteria
MAP 0011 Cytoplasmic 19,196 kDa
Iron-regulated peptidyl-prolyl cis-trans isomerase A in Mycobacterium
tuberculosis H37Rv
MAP 0034 Cytoplasmic-Membrane 44 kDa P44 protein in Mycobacterium avium subsp. avium
MAP 0047c Extracellular 41,1 kDa Lpp-LpqN family conserved in Mycobacteriaceae
MAP 0038 Unknown 48,7 kDa Hypothetical protein Mb0027 in Mycobacterium bovis AF2122/97
MAP 0187 Extracellular 23 kDa Superoxide dismutase in Mycobacterium bovis
MAP 0209c Extracellular 56,5 kDa
Protein potentially involved in peptidoglycan biosynthesis in
Mycobacterium avium subsp. avium
MAP 0210c Cytoplasmic-Membrane 30,7 kDa
Secreted antigen P36/P34 precursor in Mycobacterium bovis, maxima
ident 60%
MAP 0211 Cytoplasmic 46 kDa UDP-galactopyranose mutase glf in Mycobacterium tuberculosis
MAP 0297 Cytoplasmic 55,23 kDa Hypothetical protein Mb1161 Mycobacterium bovis AF2122/97
MAP 0334 Unknown 34,386 kDa Oxidoreductase in Mycobacterium bovis AF2122/97
MAP 0900 Cytoplasmic-Membrane 29,6–34 kDa Antigen 34 kDa in Mycobacterium tuberculosis CDC1551
MAP 0946c Cytoplasmic-Membrane 33,5 kDa Sigma factor in Mycobacterium avium 104
MAP 1012c Cytoplasmic 37,374 kDa Hypothetical protein TMAG 01006 in Mycobacterium tuberculosis
MAP 1050c Cytoplasmic 33 kDa
Peptidyl-prolyl cis-trans isomerase, cyclophilin-type conserved in
Mycobacterium
MAP 1272 Extracellular 33,4 kDa NLP/P60 family protein in Mycobacterium tuberculosis CDC1551
MAP 1293 Unknown 49,24 kDa Histidinol dehydrogenase his D in Mycobacterium tuberculosis
MAP 1308
Unknown (This protein may
have multiple localization sites.)
46 kDa
Prolipoprotein diacylglyceryl transferase lgt in Mycobacterium tubercu-
losis
MAP 1564c Unknown 23,01 kDa Short chain dehydrogenase in Mycobacterium bovis
MAP 1589c Cytoplasmic 21,60 KDa Alkyl hydroperoxide reductase subunit C in Mycobacterium tuberculosis
MAP 1653 Unknown 16,7–20 kDa Thiol peroxidase tpx in Mycobacterium tuberculosis T17
MAP 1693c Unknown 18,30 kDa
Peptidyl-prolyl cis-trans isomerase domain-containing protein con-
served in Mycobacterium
MAP 1754c Cytoplasmic-Membrane 30,84 kDa Hypothetical protein Rv2005c in Mycobacterium tuberculosis H37Rv
MAP 1889c Cytoplasmic 28 kDa Wag31 protein in Mycobacterium avium 104
MAP 1962 Cytoplasmic 53,68 kDa Glutamine synthetase glnA1 in Mycobacterium tuberculosis
MAP 2020 Unknown 26,90 kDa Cutinase in Mycobacterium bovis AF2122/97
MAP 2167 Extracellular 17 kDa
Low molecular weight protein antigen cfp2 in Mycobacterium tubercu-
losis
MAP 2182 Cytoplasmic-Membrane 16 kDa
Deazaflavin-dependent nitroreductase family protein in
Mycobacterium
MAP 2513 Cytoplasmic 36,50 kDa Alkanal monooxygenase alpha chain in Mycobacterium avium 104
MAP 2609 Cytoplasmic-Membrane 11,40 kDa
Low molecular weight T-cell antigen TB8.4 in Mycobacterium tubercu-
losis
MAP 2676c Cytoplasmic 13,89 kDa Hypothetical protein MAV 1246 in Mycobacterium avium 104
MAP 2685 Unknown 21,20 kDa
Hypothetical protein BCG 1169c in Mycobacterium bovis BCG str.
Pasteur 1173P2
MAP 2878c Cytoplasmic 25,43 kDa
Dihydrodipicolinate reductase in Mycobacterium bovis BCG str. Pasteur
1173P2
MAP 2942c Extracellular 18,30 kDa Soluble secreted antigen MPT53 in Mycobacterium tuberculosis
MAP 2956 Cytoplasmic 30,02 kDa 30S ribosomal protein S2 in Mycobacterium tuberculosis H37Rv
MAP 3175c Cytoplasmic 41,38 kDa Peptide chain release factor 2 in Mycobacterium tuberculosis H37Rv
MAP 3194 Cytoplasmic 30,46 kDa Pyruvate carboxyl transferase in Mycobacterium avium
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Table 1: Continued.
Antigen
(ORF no.)
Predicted localization
Theoretical
MW
Homology with other mycobacteria
MAP 3205 Cytoplasmic 27 kDa nuoE NADH dehydrogenase subunit E in Mycobacterium avium 104
MAP 3206 Cytoplasmic 48-49 kDa
nuoF NADH-Quinone oxidoreductase subunit F in Mycobacterium
tuberculosis
Mb 3341c Unknown 10,63 kDa
Equivalent to Rv3312A, len: 103 aa, from Mycobacterium tuberculosis
strain H37Rv
MAP 3402 Cytoplasmic 33,28 kDa Thiosulfate sulfurtransferase in Mycobacterium bovis AF2122/97
MAP 3457 Cytoplasmic 47,61 kDa
O-acetylhomoserine sulfhydrylase metC in Mycobacterium tuberculosis
T92
MAP 3491 Cytoplasmic 28,16 kDa Hydrolase in Mycobacterium tuberculosis SUMu003
MAP 3527 Unknown 35,70 kDa Serine protease PepA in Mycobacterium tuberculosis H37Rv
MAP 3627 Cytoplasmic 37,37 kDa O-methyltransferase in Mycobacterium tuberculosis H37Rv
MAP 3651 Cytoplasmic 44 kDa Acyl-CoA dehydrogenase fadE3 in Mycobacterium bovis BCG
MAP 3692 Cytoplasmic 47 kDa fabG 3-ketoacyl-ACP reductase in Mycobacterium tuberculosis H37Rv
MAP 3840 Cytoplasmic 67 kDa Heat shock protein 70, molecular chaperone DnaK in Mycobacterium
MAP 3841 Unknown 23,57 kDa Heat shock protein GrpE in Mycobacterium bovis AF2122/97
MAP 3857 Cytoplasmic 18,73 kDa
Orotate phosphoribosyltransferase phosphoribosyltransferase in
Mycobacterium tuberculosis CDC1551
MAP 3936 Cytoplasmic 57 kDa Heat shock protein 65, GroEL in Mycobacterium sp
MAP 4000c Unknown 12 kDa
Esat-6 like protein esxF in Mycobacterium and hypothetical protein
Mb3935c in Mycobacterium bovis
MAP 4143 Cytoplasmic 43,77 kDa Iron-regulated elongation factor tu in Mycobacterium tuberculosis
MAP 4147 Cytoplasmic 42,09 kDa Ferredoxin reductase in Mycobacterium tuberculosis H37Rv
MAP 4227c Cytoplasmic 30,14 kDa Hypothetical protein Rv3463 in Mycobacterium tuberculosis H37Rv
experimentally infected with M. bovis. The stronger mean
intensity values are listed in Table 2. Serum samples with
density values higher than the mean obtained with the
control (PBS) were considered positive and the numbers of
animals reactive with each protein are shown in Table 3.
The antigens selected were those that showed stronger
intensity with sera from MAP-infected animals than with
sera from non-MAP-infected animals. These antigens were
MAP 0038, MAP 0210c, MAP 1272, MAP 1693c, and MAP
0209, shown in bold in Tables 2 and 3. In addition, we
selected two antigens, MAP 2020 and MAP 2513, because
they recognized nine and six animals with PTB (Table 3),
respectively, and because they had not been previously
evaluated or reported in the literature.
These results contributed to the development of an
antigen mixture with seven antigens (MAP 0038, MAP
0210c, MAP 1272, MAP 1693c, MAP 2020, MAP 2513, and
MAP 0209c).
The ORF of MAP 1272 codes for a protein that possesses
an NLP/P60 domain of unknown function that is found
in several lipoproteins. MAP 0210 codes for the P36/Erp
protein ofM. bovis, which has been studied in our laboratory
[19]. PSORTB analysis software predicted that MAP 2513
is localized in the cytoplasm, MAP 0210c in the cytoplasm-
membrane, and that MAP 1272 andMAP 0209c are extracel-
lular. The remaining proteins were of unknown localization.
All seven of these proteins have not been previously evaluated
Control PTB infected M. bovis infected
Figure 2: Evaluation of the cocktail by a Line print immunoassay.
Result of the cocktail with seven antigens (MAP 0038, MAP 0210c,
MAP 1272, MAP 1693, MAP 2020, MAP 0209c and MAP 2513)
printed in a membrane of nitrocellulose and evaluated with the sera
from healthy animals and animals infected with MAP and M. bovis.
or reported in the literature, except for MAP 0210c, which
has been studied by Willemsen et al. [18].
The cocktail of seven antigens was printed in the nitrocel-
lulose membrane and evaluated by Line print immunoassay
with sera from animals with PTB and healthy controls and
animals experimentally infected with M. bovis (Figure 2).
By line print immunoanalysis, 14 out of 25 of the sera
from animals with PTB developed antibody response to the
cocktail. This cocktail was not recognized with the sera from
animals experimentally infected withM. bovis here evaluated
and two serum samples from healthy animals gave a very
weak signal (Figure 2).
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Table 2: Spot intensities for protein macroarrays.
Antigen assayed
Mean spot intensity of proteins exposed to sera
control
(n = 10)
PTB infected
(n = 25)
TB infected
(n = 8)
MAP 0011 112 135 0
MAP 0034 240 247 0
MAP 0038 141 860 0
MAP 0047 344 309 0
MAP 0187c 184 0 0
MAP 0209c 367 499 0
MAP 0210c 0 398 0
MAP 0211 0 572 0
MAP 0297 117 225 130
MAP 0334 108 167 1
MAP 0900 0 749 0
MAP 0946 218 900 295
MAP 1012 280 0 0
MAP 1050 268 275 0
MAP 1272 223 733 0
MAP 1293 585 481 396
MAP 1308 163 894 0
MAP 1564 259 344 0
MAP 1589c 323 682 466
MAP 1653 398 844 461
MAP 1693 226 967 209
MAP 1754 0 142 27
MAP 1889c 280 180 494
MAP1962 341 270 354
MAP 2020 0 150 228
MAP 2167 315 0 0
MAP 2182c 223 117 192
MAP 2513 41 164 291
MAP 2609 137 308 0
MAP 2676 201 138 0
MAP 2685 317 323 0
MAP 2878 307 323 0
MAP 2942 136 251 0
MAP 2956 345 119 424
MAP 3175 343 130 0
MAP 3194 0 100 0
MAP 3205 0 0 0
MAP 3206 100 200 0
Mb 3341 159 171 178
MAP 3402 205 178 250
MAP 3457 447 365 325
MAP3491 286 454 177
MAP 3527 528 414 635
MAP 3627 207 265 0
Table 2: Continued.
Antigen assayed
Mean spot intensity of proteins exposed to sera
control
(n = 10)
PTB infected
(n = 25)
TB infected
(n = 8)
MAP 3651 1000 906 958
MAP 3692c 305 212 0
MAP 3840 0 198 712
MAP 3841 707 678 457
MAP 3857 373 267 265
MAP 3936 381 544 691
MAP 4000c 134 242 0
MAP4143 413 397 439
MAP 4147 1000 556 0
MAP 4227 138 101 0
PPDA 208 105 256
PPDB 346 531 1468
PPA-3 131 609 108
Cocktail 140 1460 0
Intensities were obtained using ImageQuant TL Array Version 7.0 Software,
(GE Healthcare, Pittsburgh, PA). Antigens selected to evaluate as cocktail
are shown in bold. PPA-3: Paratuberculosis protoplasmatic antigen (Allied
Monitor, Inc. USA); PPDA and PPDB: avian- and bovine-derivative protein
purified, respectively (Prionic Switzerland). Cocktail: mix of the 7 antigens
shown in bold.
In addition, ELISAs with PPA-3 and with the cocktail
with seven antigens were evaluated with sera from animals
with PTB (n = 25), healthy animals (n = 26), and animals
experimentally infected with M. bovis (n = 17).
The ELISA-PPA-3 test recognized 16 out of the 25
animals with PTB (64%) but also 12 of the 17 animals
experimentally infected with M. bovis, while the ELISA-
cocktail detected 18 of 25 animals with PTB (72%) and
only 3 of the 17 animals experimentally infected with M.
bovis (Figure 3). Both ELISAs did not have a reaction with
sera from non-infected controls; however, when using sera
fromM. bovis-infected, ELISA-PPA-3 test recognized (12/17)
70,5% of these animals and ELISA-cocktail (3/17) 17,6% of
these animals.
This new ELISA for bovine PTB showed 72% of sensitiv-
ity and had higher specificity than the ELISA with PPA-3 as
antigen, using animals experimentally infected withM. bovis.
4. Discussion
The early and specific diagnosis of PTB is still a challenge. It
has generally been believed that the early immune response
to infection with MAP consisted primarily of a cellular
immune response characterized by interferon gamma pro-
duction, and this response would later be replaced by
antibody production. However, some studies have shown
that antibodies appear much earlier and therefore ELISA
could be used as an early diagnostic tool [6–8]. Then it
is necessary to characterize MAP antigens to increase the
sensitivity and specificity of the ELISA test for PTB diagnosis.
The MAP genome sequencing represented a significant
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Table 3: Reactivity of bovine sera to the panel of selected antigens
from MAP.
Antigen assayed
No. of sera with positive recognition
control
(n = 10)
PTB infected
(n = 25)
TB infected
(n = 8)
MAP 0011 0 5 4
MAP 0034 5 5 0
MAP 0038 3 8 0
MAP 0047 3 4 0
MAP 0187c 1 1 0
MAP 0209c 4 9 0
MAP 0210c 0 8 0
MAP 0211 0 6 0
MAP 0297 2 4 1
MAP 0334 2 15 1
MAP 0900 0 3 0
MAP 0946 1 8 0
MAP 1012 2 0 0
MAP 1050 4 9 0
MAP 1272 2 8 0
MAP 1293 10 13 1
MAP 1308 2 2 0
MAP 1564 5 1 0
MAP 1589c 2 9 2
MAP 1653 10 20 8
MAP 1693 3 12 2
MAP 1754 0 5 4
MAP 1889c 7 7 3
MAP 1962 3 16 5
MAP 2020 0 9 2
MAP 2167 3 0 0
MAP 2182c 5 1 2
MAP 2513 1 6 2
MAP 2609 2 4 0
MAP 2676 1 4 0
MAP 2685 10 2 0
MAP 2878 10 2 0
MAP 2942 2 7 0
MAP 2956 1 1 1
MAP 3175 4 4 4
MAP 3194 0 1 0
MAP 3205 0 0 0
MAP 3206 1 5 0
Mb 3341 4 6 3
MAP 3402 2 20 1
MAP 3457 10 8 4
MAP 3491 7 7 1
MAP 3527 6 25 8
MAP 3627 3 4 0
Table 3: Continued.
Antigen assayed
No. of sera with positive recognition
control
(n = 10)
PTB infected
(n = 25)
TB infected
(n = 8)
MAP 3651 10 14 8
MAP 3692c 5 8 0
MAP 3840 0 3 3
MAP 3841 10 14 1
MAP 3857 10 4 4
MAP 3936 5 8 4
MAP 4000c 3 5 0
MAP 4143 8 16 7
MAP 4147 1 3 0
MAP 4227 1 1 1
PPDA 6 1 4
PPDB 4 16 3
PPA-3 1 18 2
Cocktail 2 14 0
20 uL of antigens were applied to a nitrocellulose membrane (Amersham
Hybond-ECL, GE Healthcare Life Sciences, UK) at a concentration of
100 ug/mL, using a semiautomatic aerolizer (Camag Scientific Inc., Wilm-
ington, Delaware). Membranes were evaluated by immunoblotting using
sera from healthy and infected animals. Numbers of sera with antibody
response are indicated. Samples with intensities values higher than the
media obtained with the control (PBS) were considered positive. Antigens
selected to evaluate as cocktail are shown in bold. PPA-3: Paratuberculosis
protoplasmatic antigen (AlliedMonitor, Inc. USA); PPDA and PPDB: avian-
and bovine-derivative protein purified (Prionic Switzerland ); Cocktail: Mix
of the 7 antigens shown in bold.
advance and will most likely contribute with new tools for
diagnosis. The evaluation of a specific panel of antigens such
as that studied in the present work is the first step in the
selection of candidates to be studied at different herds with
PTB of our country. This is an important area, since novel
antigens that could improve the diagnosis of MAP-infected
cattle are needed.
The proteomic approach has been used to define spe-
cific antigens by 2D fraction of MAP proteins by several
researchers [20–24]. Another approach to obtain specific
antigens is to express recombinant proteins from cloned
MAP-coding sequences and use them to construct a protein
array [15]. Here we selected MAP proteins by 1D or 2D
electrophoresis and developed macroarrays by line print of
these proteins. These macroarrays were probed with sera
from animals with PTB and healthy controls and animals
experimentally infected with M. bovis.
After evaluation of 54 proteins of MAP with sera from
PTB-infected, experimentally infected with M. bovis and
healthy animals, we selected seven proteins, which were
incorporated in an ELISA to develop an antigen-based diag-
nostic test (ELISA-cocktail). This new ELISA for bovine PTB
showed 72% of sensitivity and had higher specificity than
the ELISA with PPA-3 as antigen (Figure 3). This sensitivity
was based on 25 animals from MAP fecal culture-positive or
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Figure 3: Reactivity of bovine sera to the cocktail by ELISA.
Comparison of the diagnostic performance of using PPA-3 (Allied
monitor) and the antigen cocktail (MAP 0038, MAP 0210c, MAP
1272, MAP 1693, MAP 2020, MAP 0209c, and MAP 2513).
ELISA-positive cattle, because naturally infected cattle may
represent various stages ofMAP infection and serum samples
only from culture-positive animals can express differentiated
antigen patterns [25]. In addition, the use of only culture-
positive animals to estimate the sensitivity of ELISA may
increase the values of the test because most culture-positive
animals are also ELISA-positive [11].
The results presented here suggest that several specific
antigens can improve the detection of MAP infection. In
fact, the profiles of antibody response varied considerably
and then the antibody response to single antigens was not
prominent, while simultaneous usage of several recombinant
antigens is able to recognize the ongoing antibody response
over time in the course of infection.
In summary, here we identified novel antigens of MAP
by using multiple antigen print immunoassay. Based on
this knowledge, we developed an antigen cocktail, which
increased the correct diagnosis of MAP-infected animals
in comparison with the results of ELISA-PPA-3. The study
presents an antigen cocktail, which could be of diagnostic
significance for further researches. However, the cocktail
needs to be evaluated by larger sample sizes in order to
estimate its sensitivity and specificity. In addition, the results
here shown with the 54 proteins, indicated that other
proteins not included were also good candidates. Then, new
cocktails should be incorporated and evaluated to increase
the sensitivity and specificity of the ELISA test for diagnosis
of PTB.
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